Observational prospective study describing the global patient care and follow-up of prostate cancer patients treated with Degarelix (DUO study (Dialogue in Uro-Oncology))

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS18906
• Study ID:
  46959
• Official title and acronym:
  Observational prospective study describing the global patient care and follow-up of prostate cancer patients treated with Degarelix (DUO study (Dialogue in Uro-Oncology))
• DARWIN EU® study:
  No
• Study countries:
  France
• Study description:
  The DUO study's main objective is to evaluate, in the real life, the prevalence of cardiovascular comorbidities among prostate cancer patients receiving Degarelix, before treatment. This study will also assess, at the initiation of therapy, the prevalence of osteoporosis, metabolic comorbidities, depression, sexual and geriatric patients suffering from prostate cancer.
• Study status:
  Finalised

Research institutions and networks

Institutions

Multiple centres: 60 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned:05/08/2015

Actual:11/04/2016

Study start date

Planned:30/06/2017

Actual:27/06/2017

Data analysis start date

Planned:31/03/2019

Actual:04/03/2019

Date of final study report

Planned:30/09/2019

Actual:30/11/2021

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Ferring SAS

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable